Next Generation Sequencing (NGS) Market Size, Share & Trends Analysis Report By Product (Targeted Sequencing, Whole Exome Sequencing, Whole Genome Sequencing), By Applications (Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics), By End Use, By Region, and Segment Forecasts - 2035

Next Generation Sequencing (NGS) Market Overview

The global next generation sequencing (ngs) market size was valued at USD 3945.41 million in 2025 and is projected to grow from USD 4079.55 million in 2026 to USD 5727.36 million by 2035, exhibiting a CAGR of 3.4% during the forecast period.

The next generation sequencing market is entering a more application-driven phase as sequencing platforms become faster, more scalable, and increasingly integrated with automated sample preparation, cloud-based analysis, and artificial intelligence-assisted interpretation. During 2026, demand is being supported by broader adoption of whole genome sequencing, targeted sequencing, and whole exome sequencing across research and translational workflows. High-throughput systems are also becoming more efficient, with the NovaSeq X Plus platform capable of generating approximately 16 to 21 terabases of data from a dual-flow-cell run, while long-read platforms are expanding their role in structural-variant detection, genome assembly, methylation analysis, and complex disease research.

United States demand remains particularly influential because of the concentration of genomic research institutions, pharmaceutical development programs, advanced sequencing laboratories, and clinical research infrastructure. The market is also benefiting from increasing use of sequencing for oncology research, rare-disease investigation, population genomics, and biomarker discovery. In 2026, production-scale sequencing platforms can support more than 100 human whole genomes in a single high-throughput run, strengthening the economic case for large cohort studies and centralized sequencing facilities. At the same time, long-read sequencing is gaining attention for applications where conventional short-read approaches have limitations in resolving repetitive regions, structural variants, haplotypes, and epigenetic characteristics.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Whole Genome Sequencing is expected to lead with an estimated 45% share, supported by population genomics, rare-disease research, oncology studies, and increasing demand for comprehensive genomic characterization.
• Leading Application: Academic and Clinical Research Centers are projected to account for approximately 44% of demand, reflecting expanding genomic studies, translational research programs, and large-scale sequencing projects across more than 3 major research domains.
• Leading Region: North America is estimated to hold the leading regional position with about 38% share, supported by advanced genomic infrastructure, strong clinical research activity, and extensive sequencing adoption across pharmaceutical and biotechnology programs.
• Fastest Growing Region: Asia Pacific is expected to register the fastest regional expansion at approximately 6.2% annually, driven by increasing sequencing capacity, population-scale genomics initiatives, biotechnology investment, and expanding research infrastructure across major markets.
• Technology Trend: High-throughput sequencing is advancing rapidly, with the NovaSeq X Plus capable of producing approximately 16 to 21 terabases per dual-flow-cell run, supporting large cohorts, whole genome projects, and data-intensive genomic research.
• Market Driver: The increasing scale of genomic studies is strengthening demand, with production-scale sequencing platforms capable of processing more than 128 human whole genomes in a single run under optimized high-throughput workflows.
• Competitive Landscape: Long-read sequencing competition is intensifying as platforms target lower operating costs; PacBio introduced chemistry designed to reduce scaled whole-genome sequencing costs by as much as 40%, increasing pressure for efficiency and accessibility.
• Future Outlook: Real-time and multiomic sequencing will gain importance as high-output systems expand, with PromethION platforms supporting up to 48 individually addressable flow cells and enabling large-scale DNA, RNA, and population genomics workflows.

Latest Trends

The NGS market is increasingly shifting toward higher throughput combined with lower workflow complexity. Sequencing providers are improving chemistry, flow-cell density, read accuracy, automation, and integrated data analysis so laboratories can process larger sample volumes without proportionally increasing operational requirements. Production-scale platforms are now designed around tens of billions of sequencing locations per flow cell, while advanced sequencing-by-synthesis chemistry can provide approximately two-fold faster incorporation times compared with earlier chemistry approaches. These improvements are encouraging academic and clinical research centers to expand cohort sizes and increase sequencing depth for applications where rare variants or low-frequency genomic signals must be detected.

Long-read sequencing is simultaneously becoming a stronger component of the competitive landscape. Technologies capable of generating reads across difficult genomic regions are being positioned for structural-variant analysis, genome assembly, methylation studies, transcriptomics, and complex disease research. PacBio has introduced workflows capable of supporting HiFi sequencing from DNA inputs as low as 1 ng, while Oxford Nanopore continues developing real-time sequencing and adaptive-sampling workflows. The convergence of sequencing with machine learning is another important trend, with advanced computational pipelines increasingly supporting basecalling, variant identification, secondary analysis, and interpretation. By 2027, the market is expected to place greater emphasis on complete workflow integration rather than sequencing hardware performance alone.

Market Dynamics

Driver

""Growing demand for comprehensive genomic analysis is expanding sequencing adoption across research and translational workflows.""

The strongest market driver is the increasing requirement for detailed genomic information across disease research, drug discovery, population studies, and molecular diagnostics. Whole Genome Sequencing is benefiting particularly from projects requiring broad variant detection rather than analysis of a limited genomic region. Production-scale systems capable of generating more than 10 terabases in a single run are enabling laboratories to increase sample throughput while maintaining deeper sequencing coverage. This capability is particularly valuable for population-scale projects involving thousands of samples and for pharmaceutical research programs investigating genomic associations with therapeutic response.

The expansion of precision medicine is further strengthening sequencing demand. Academic and Clinical Research Centers are increasingly combining sequencing results with phenotype, clinical, and longitudinal information to improve disease characterization. Pharmaceutical and Biotechnology Companies are also using genomic information during target identification, biomarker development, patient stratification, and drug-response studies. As sequencing workflows become more automated, laboratories can move from small experimental batches toward standardized processing involving hundreds or thousands of samples, improving utilization of high-throughput infrastructure.

Restraint

""Complex workflows, infrastructure requirements, and data-management demands continue to restrict adoption among smaller laboratories.""

Despite technological improvements, NGS implementation remains operationally demanding for organizations without established genomic infrastructure. High-throughput sequencing can generate terabytes of information within a single run, creating requirements for storage, high-performance computing, cybersecurity, data transfer, and bioinformatics expertise. A laboratory adopting a production-scale workflow must therefore consider multiple cost and operational variables beyond the sequencer itself. These requirements can slow adoption among smaller academic facilities and healthcare organizations where sequencing volumes are insufficient to fully utilize advanced platforms.

Data interpretation also remains a significant constraint. A sequencing workflow can involve sample preparation, library construction, sequencing, quality control, alignment, variant calling, annotation, and biological interpretation, with each stage introducing potential sources of complexity. Clinical and translational applications can require additional validation and documentation. As datasets become larger, the need for skilled bioinformaticians and standardized analytical pipelines becomes more important. This creates a capability gap between well-funded genomic centers and institutions that are still developing their sequencing infrastructure.

Opportunity

""Expansion of scalable sequencing and decentralized workflows is opening new opportunities across emerging research and clinical environments.""

The expansion of sequencing into decentralized and application-specific environments represents a substantial opportunity. Portable and modular platforms are allowing laboratories to perform sequencing closer to the point of sample collection instead of depending entirely on centralized facilities. Oxford Nanopore platforms, for example, span portable systems through high-output benchtop configurations, enabling laboratories to select sequencing capacity according to project size. This flexibility can support infectious disease surveillance, field genomics, agricultural research, microbial identification, and rapid research applications where turnaround time is important.

Emerging markets also provide an opportunity because genomic research infrastructure is expanding across Asia Pacific, Latin America, and selected Middle Eastern markets. Governments, universities, hospitals, and biotechnology companies are increasingly investing in population genomics, cancer research, rare-disease programs, and biotechnology capabilities. At the same time, lower-input sequencing protocols are widening the addressable sample base. PacBio has demonstrated workflows supporting HiFi sequencing from 1 ng of DNA, showing how reduced sample requirements can make advanced sequencing more practical for limited or difficult-to-obtain biological material.

Challenge

""Managing rapidly increasing sequencing data while maintaining accuracy, interoperability, and workflow consistency remains a major industry challenge.""

The growing scale of sequencing output is creating a parallel challenge in data management and interpretation. A single production-scale sequencing run can generate several terabases of information, requiring robust infrastructure for data transfer, storage, backup, compression, and analysis. Sequencing organizations must also maintain consistent quality across instruments, reagent lots, sample types, and analytical pipelines. These requirements become more complex when research teams combine short-read and long-read datasets or integrate genomic information with transcriptomic and epigenomic data.

Another challenge is balancing accuracy, speed, throughput, and cost for different applications. Academic and Clinical Research Centers may prioritize comprehensive data and analytical flexibility, whereas Pharmaceutical and Biotechnology Companies may require standardized workflows that can process large cohorts efficiently. Hospitals and Clinics may place greater emphasis on turnaround time, reproducibility, workflow simplicity, and clinical integration. Consequently, sequencing providers must continue improving chemistry, automation, computational analysis, and software interoperability without creating additional operational complexity for end users.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Targeted Sequencing: Targeted Sequencing is estimated to account for 32% of the global next generation sequencing market during the forecast period. Its adoption remains strong because it concentrates sequencing resources on selected genes or genomic regions, supporting focused oncology research, inherited-disease studies, biomarker investigations, and validation workflows. The approach can reduce unnecessary sequencing output and analytical burden when research objectives are limited to defined genomic targets. Demand is also supported by laboratories seeking reproducible workflows that can process larger sample batches while maintaining manageable data volumes. Its 32% share reflects continued relevance across both exploratory and translational research, particularly where researchers require deeper coverage of selected genomic regions rather than comprehensive genome characterization.

Whole Exome Sequencing: Whole Exome Sequencing is projected to represent 23% of the market. The technology remains important for identifying coding-region variants associated with rare diseases, inherited disorders, cancer biology, and phenotype-driven research. Although the exome represents only about 1% to 2% of the human genome, it contains a substantial proportion of currently known disease-associated variants, making it an efficient option for studies where coding mutations are the primary research focus. Improvements in library preparation, sequencing chemistry, enrichment methods, and computational interpretation are supporting greater sample throughput. The 23% share indicates sustained demand from research programs that require broader variant discovery than targeted panels but do not require the complete genomic coverage provided by Whole Genome Sequencing.

Whole Genome Sequencing: Whole Genome Sequencing is expected to hold the largest product share at 45% during the forecast period. Its leading position is supported by the ability to examine coding and non-coding regions, structural variants, copy-number changes, and other genomic characteristics within a single workflow. The increasing scale of population genomics and rare-disease research is particularly favorable for this segment. High-throughput platforms can now generate multiple terabases of sequence information during production-scale runs, allowing large cohorts to be processed more efficiently. The 45% share also reflects growing interest in comprehensive genomic profiling, improved sequencing economics, and the use of Whole Genome Sequencing as a foundation for increasingly data-intensive precision research programs.

By Applications

Academic and Clinical Research Centers: Academic and Clinical Research Centers are expected to represent 44% of total NGS market demand, making this the leading application segment. Universities, genomic institutes, and clinical research organizations are expanding sequencing programs for oncology, rare diseases, population studies, infectious disease research, and molecular biology. Large-scale research projects increasingly require thousands of samples, creating demand for high-throughput platforms and standardized workflows. The 44% share reflects the broad research applicability of NGS and the continued role of academic institutions in validating emerging sequencing technologies. Increasing collaboration between research centers and biotechnology organizations is also encouraging the movement of sequencing discoveries from exploratory studies toward translational applications.

Pharmaceutical and Biotechnology Companies: Pharmaceutical and Biotechnology Companies are projected to account for 34% of market demand. These organizations increasingly incorporate sequencing into target discovery, biomarker identification, patient stratification, drug-response research, and therapeutic development. Genomic datasets can help researchers identify molecular differences between patient populations and support the development of more precisely defined clinical-study cohorts. The 34% share demonstrates the importance of sequencing in modern drug-development workflows. Demand is also being reinforced by the expansion of companion research programs, multiomic investigations, and computational approaches that combine sequencing information with biological and clinical datasets. As pharmaceutical pipelines become more genomically informed, sequencing is expected to remain a core research technology.

Hospitals and Clinics: Hospitals and Clinics are estimated to hold a 22% share of the market. Adoption is increasing as healthcare organizations strengthen genomic research capabilities and incorporate sequencing into specialized clinical investigation programs. Hospitals are particularly interested in applications involving oncology, rare diseases, hereditary conditions, and treatment-response research where genomic information can provide additional biological insight. However, the segment remains smaller than Academic and Clinical Research Centers and Pharmaceutical and Biotechnology Companies because implementation can require specialized personnel, analytical infrastructure, validation procedures, and integration with existing laboratory systems. Continued improvements in workflow automation, turnaround time, and interpretation software should gradually expand the role of NGS within hospital-based genomic programs.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is expected to remain the leading regional market, accounting for 38% of global NGS demand during the forecast period. The region benefits from a mature sequencing ecosystem involving advanced research institutions, pharmaceutical and biotechnology companies, specialized genomic laboratories, and sophisticated healthcare infrastructure. Strong investment in precision medicine and population-scale genomic research continues to support the deployment of high-throughput sequencing platforms. The 38% share is consistent with North America's established position and its broad adoption of Whole Genome Sequencing, Targeted Sequencing, and Whole Exome Sequencing across research-intensive applications.

The United States represents the principal contributor to regional demand, supported by extensive genomic research programs and a large concentration of sequencing technology developers and users. Pharmaceutical and Biotechnology Companies are increasingly using sequencing for biomarker research and therapeutic development, while Academic and Clinical Research Centers continue to generate substantial sequencing volumes. North America is also a major early adopter of automation and artificial intelligence-assisted genomic analysis. Increasing availability of high-output instruments capable of generating several terabases per run should help research organizations process larger cohorts while improving laboratory productivity.

Europe

Europe is projected to account for 27% of the global next generation sequencing market. The region has a strong foundation of academic genomics, molecular research, biotechnology development, and clinical research infrastructure. National and cross-border genomic initiatives are encouraging standardized sequencing workflows and larger collaborative datasets. Demand for Whole Genome Sequencing is increasing as research organizations move toward comprehensive genomic characterization, while Targeted Sequencing continues to support focused molecular research. The 27% regional share reflects Europe's established sequencing capacity and the continued expansion of genomic applications across major healthcare and biotechnology markets.

European demand is also being shaped by greater emphasis on data governance, interoperability, laboratory standardization, and responsible handling of genomic information. These requirements encourage organizations to invest in structured sequencing workflows and analytical systems capable of maintaining consistent quality across large datasets. Pharmaceutical and Biotechnology Companies are using NGS for biomarker discovery and research-stage patient stratification, while Academic and Clinical Research Centers continue to conduct large-scale disease and population studies. Continued development of centralized genomic infrastructure and collaborative research networks should support steady adoption throughout the forecast period.

Asia Pacific

Asia Pacific is estimated to represent 24% of the global market and is expected to be the fastest-growing regional market, with an estimated annual growth rate of 6.2%. Expanding biotechnology infrastructure, rising genomic research activity, growing sequencing capacity, and increasing investment in population genomics are supporting this trajectory. China, Japan, South Korea, India, Singapore, and Australia are contributing to regional expansion through investments in genomic research and biotechnology capabilities. The 24% share demonstrates the region's increasing importance while its 6.2% growth rate indicates stronger expansion potential than the more mature North American and European markets.

Asia Pacific is also experiencing increasing demand from Pharmaceutical and Biotechnology Companies seeking genomic data for drug research, biomarker development, and disease studies. Academic and Clinical Research Centers are expanding sequencing capabilities as research programs become more data intensive. Improvements in sequencing throughput and laboratory automation are helping reduce operational barriers, while localized sequencing infrastructure can shorten sample-processing timelines. The combination of a large research population, expanding healthcare capabilities, and increasing biotechnology investment is expected to make Asia Pacific one of the most important sources of incremental NGS demand through 2035.

Latin America

Latin America is expected to account for 6% of the global next generation sequencing market. Adoption is being supported by expanding molecular research, infectious-disease studies, oncology research, agricultural and biological investigations, and growing collaboration between universities and biotechnology organizations. Although sequencing infrastructure is less extensive than in North America, Europe, and Asia Pacific, investment in laboratory capabilities is gradually increasing. The 6% share reflects a developing market in which centralized sequencing facilities and collaborative research models can help organizations access advanced technologies without requiring every institution to maintain a complete high-throughput sequencing infrastructure.

Regional demand is expected to benefit from improvements in sequencing accessibility and analytical services. Academic and Clinical Research Centers remain important users because research institutions are increasingly studying region-specific disease patterns and population genetics. Pharmaceutical and Biotechnology Companies are also creating opportunities through clinical research and biomarker programs. Greater availability of targeted workflows can be particularly useful where sample volumes are smaller or research objectives focus on selected genomic regions. As laboratory capabilities mature, the region should gradually broaden its adoption across Whole Exome Sequencing and Whole Genome Sequencing applications.

Middle East and Africa

The Middle East and Africa region is projected to hold 5% of the global market. Growth is being supported by increasing interest in genomics, inherited-disease research, oncology, population studies, and biotechnology development. Several research institutions are strengthening sequencing capabilities through laboratory modernization and collaboration with international organizations. The region's 5% share reflects an emerging market where adoption remains concentrated in leading research centers and specialized laboratories. Improvements in equipment accessibility, bioinformatics capabilities, and sequencing services are gradually creating a broader foundation for NGS utilization.

Longer-term opportunities are linked to the region's need for genomic research addressing inherited disorders, population-specific genetic characteristics, and disease surveillance. Academic and Clinical Research Centers are likely to remain the primary adoption base, while Pharmaceutical and Biotechnology Companies can contribute through clinical research and drug-development programs. Portable and scalable sequencing technologies may be particularly relevant where centralized infrastructure is limited. Increased training of genomic specialists and development of regional bioinformatics capacity could improve utilization of sequencing systems and support gradual expansion of the market beyond major research hubs.

List of Top Next Generation Sequencing (NGS) Companies

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences of California
• Beijing Genomics Institute
• Qiagen
• Roche
• Agilent Technologies
• Perkinelmer
• Genomatix
• PierianDx
• Eurofins Scientific
• Gatc Biotech
• Oxford Nanopore Technologies
• Bio-Rad Laboratories
• DNASTAR
• Biomatters
• Partek
• New England Biolabs
• Myriad Genetics
• Macrogen

Top 2 Companies Market Share

Illumina: Illumina is estimated to command approximately 31% of the global NGS platform market, giving it the strongest individual competitive position. Its broad sequencing portfolio spans high-throughput and mid-throughput workflows, supporting applications ranging from targeted research to Whole Genome Sequencing. The company continues to emphasize sequencing speed, throughput, accuracy, and operating efficiency. Its large installed base across Academic and Clinical Research Centers and Pharmaceutical and Biotechnology Companies provides substantial ecosystem strength. Continued improvements in sequencing chemistry and platform productivity are helping Illumina defend its position as demand shifts toward larger genomic cohorts and increasingly standardized sequencing workflows.

Thermo Fisher Scientific: Thermo Fisher Scientific is estimated to hold approximately 18% of the global NGS platform market, placing it among the strongest competitors. Its competitive position is supported by sequencing systems, sample preparation capabilities, consumables, and laboratory technologies that can be integrated into broader genomic workflows. The company's extensive presence across research and clinical environments provides access to diverse customer groups. With an estimated combined share of 49% for the top two companies, the market retains a significant concentration at the leading end while other participants compete through long-read sequencing, specialized workflows, bioinformatics, regional services, and application-specific technologies.

Investment Analysis

Investment activity in the NGS market is increasingly moving beyond sequencing instruments toward complete genomic workflows. Companies and research organizations are allocating resources to automation, library preparation, high-performance computing, cloud-enabled analysis, artificial intelligence, and data-management infrastructure. High-throughput platforms capable of generating multiple terabases per run are encouraging investment in centralized sequencing facilities because larger sample volumes can improve utilization. Investment priorities are also expanding toward long-read sequencing, where improved accuracy and read length can address genomic regions that remain difficult to characterize using conventional short-read approaches.

Asia Pacific represents a particularly important investment opportunity because its estimated 24% market share is paired with the fastest projected regional growth rate of 6.2% annually. Investment is being directed toward genomic laboratories, biotechnology research, population sequencing, and clinical research capabilities. North America and Europe remain important destinations for advanced platform development and large-scale genomic programs because they collectively represent 65% of global market demand. Investors are increasingly evaluating companies based on platform scalability, consumable utilization, recurring workflow demand, computational capabilities, and the ability to support multiple sequencing applications rather than hardware sales alone.

New Product Development

New product development is concentrating on improving throughput, accuracy, read length, turnaround time, and overall workflow efficiency. High-throughput short-read platforms are being refined to support substantially larger sequencing batches, while long-read technologies are improving accuracy and sample-input flexibility. PacBio's continued development of HiFi workflows demonstrates the industry's movement toward lower-input sequencing, with protocols capable of working with DNA inputs around 1 ng. Oxford Nanopore is simultaneously expanding real-time sequencing capabilities and scalable flow-cell configurations. These developments are widening the range of research projects that can use advanced sequencing without requiring exceptionally large sample quantities.

Software and analytical innovation is becoming equally important in new product development. Sequencing providers are increasingly integrating automated quality control, basecalling, variant analysis, genomic interpretation, and visualization into unified workflows. Artificial intelligence is being applied to improve signal interpretation and identify complex genomic patterns, while cloud-compatible pipelines are helping research teams manage larger datasets. Product development is also moving toward interoperability between instruments and analysis systems so laboratories can combine sequencing technologies more efficiently. Over the next several years, successful products are likely to emphasize complete workflows that reduce hands-on steps while maintaining high accuracy across large sample batches.

Five Recent Developments

• January 2024: Illumina expanded the sequencing ecosystem around its latest high-throughput platforms, emphasizing higher output, faster workflows, and improved cost efficiency for large-scale genomic studies. Platform improvements strengthened support for Whole Genome Sequencing programs involving increasingly large sample cohorts.
• April 2024: Pacific Biosciences advanced its HiFi sequencing workflow with lower DNA-input requirements, demonstrating the ability to generate high-quality sequencing information from approximately 1 ng of DNA. The development improved the practicality of long-read sequencing for limited or difficult biological samples.
• September 2024: Oxford Nanopore Technologies continued expanding scalable real-time sequencing capabilities, supporting configurations ranging from portable instruments to high-output systems. The development strengthened the use of long-read sequencing for rapid genomic analysis, structural-variant research, and large-scale population studies.
• February 2025: Thermo Fisher Scientific continued developing sequencing and sample-preparation workflows aimed at improving laboratory automation and processing consistency. Greater integration between sample preparation and sequencing workflows is helping research laboratories handle larger batches while reducing manual intervention across multi-step genomic processes.
• March 2026: PacBio continued advancing high-fidelity sequencing technology with an emphasis on improving whole-genome sequencing economics and scalability. Its latest chemistry development targeted reductions in scaled sequencing costs of up to 40%, increasing competitive pressure across short-read and long-read sequencing platforms.

Report Coverage

The next generation sequencing market analysis covers Targeted Sequencing, Whole Exome Sequencing, and Whole Genome Sequencing across Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, and Hospitals and Clinics. The assessment evaluates technology adoption, workflow modernization, sequencing throughput, laboratory automation, data-analysis requirements, precision research, long-read sequencing, and the expanding role of computational technologies. Whole Genome Sequencing represents the leading product category with an estimated 45% share, while Academic and Clinical Research Centers lead applications with approximately 44% of market demand.

The regional assessment covers North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with respective market shares of 38%, 27%, 24%, 6%, and 5%, totaling exactly 100%. North America maintains the largest regional position, while Asia Pacific represents the fastest-growing region at an estimated 6.2% annual growth rate. The competitive assessment includes Illumina, Thermo Fisher Scientific, Pacific Biosciences of California, Beijing Genomics Institute, Qiagen, Roche, Agilent Technologies, Perkinelmer, Genomatix, PierianDx, Eurofins Scientific, Gatc Biotech, Oxford Nanopore Technologies, Bio-Rad Laboratories, DNASTAR, Biomatters, Partek, New England Biolabs, Myriad Genetics, and Macrogen.